tiprankstipranks
Inventiva Advances MASH Clinical Trial, Secures Funding
Company Announcements

Inventiva Advances MASH Clinical Trial, Secures Funding

Inventiva (IVA) has released an update.

Don't Miss our Black Friday Offers:

Inventiva, a biopharmaceutical company, has enrolled over 85% of patients in its NATiV3 clinical trial, with strong indications of positive biomarker evolution in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company reported a cash position of €10.1 million as of mid-2024 and has extended its cash runway until mid-October 2024 after securing €20.1 million through royalty certificates. Inventiva is actively pursuing additional financing options to support its ongoing clinical trials and future operations.

For further insights into IVA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInventiva Reports Voting Rights and Advances Clinical Trials
TipRanks Auto-Generated NewsdeskInventiva Prepares for Key General Meeting and Financing Plans
TipRanks Auto-Generated NewsdeskInventiva’s Phase 2 Results Boost Hope for MASH Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App